Clinical trial · Observational
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
NCT05547737CI-TRIAL-00060946NSCLCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the effectiveness and safety of Camrelizumab based cross-line therapy for patients with advanced NSCLC in the real world
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Objective Response Rate (ORR) in second-line treatment of patients with non-small cell lung cancer based on Camrelizumab regimen
- timeFrame
- Up to 12 months
- description
- CR+PR
Secondary outcomes (4)
- measure
- Evaluation of Progression Free survival (PFS) in patients with non-small cell lung cancer based on first-line/second-line treatment with Camrelizumab
- timeFrame
- Up to 36 months
- description
- Progression free survival (PFS) according to RECIST 1.1
- measure
- Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen
- timeFrame
- Up to 12 months
- description
- Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed informed consent and volunteered to join the study 2. Aged \>=18 years 3. Patients with stage IIIb, IV, or relapsed non-small cell lung cancer diagnosed cytologically or histopathologically as EGFR/ALK- 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 5. At least one measurable lesion (according to RECIST 1.1) 6. No prior systemic therapy for advanced/metastatic NSCLC 7. contraception Exclusion Criteria: 1. Those who are allergic to drug treatment； 2. Patients who were also treated with other immunodrugs or therapies； 3. Patients who are participating in other intervention studies； 4. Patients with other malignant tumors at the same time； 5. Pregnant or lactating women； 6. The investigator did not consider the patients eligible to participate in the study under any other circumstances.
References
Publications (0)
Data not yet available
No reference posted for this study.